Genetic analysis is currently offering glimpses into molecular mechanisms underlying such neuropsychiatric disorders as schizophrenia, bipolar disorder and autism. After years of frustration, success in identifying disease-associated DNA sequence variation has followed from new genomic technologies, new genome data resources, and global collaborations that could achieve the scale necessary to find the genes underlying highly polygenic disorders. Here we describe early results from genome-scale studies of large numbers of subjects and the emerging significance of these results for neurobiology.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Future Journal of Pharmaceutical Sciences Open Access 26 May 2021
Scientific Reports Open Access 31 March 2021
Scientific Reports Open Access 17 September 2019
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Hyman, S.E. Revolution stalled. Sci. Transl. Med. 4, 155cm11 (2012).
Jack, C.R. Jr. & Holtzman, D.M. Biomarker modeling of Alzheimer's disease. Neuron 80, 1347–1358 (2013).
Sullivan, P.F., Daly, M.J. & O'Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat. Rev. Genet. 13, 537–551 (2012).
Yang, J. et al. Common SNPs explain a large proportion of the heritability for human height. Nat. Genet. 42, 565–569 (2010).
Cross-Disorder Group of the Psychiatric Genomics Consortium and Genetic Risk Outcome of Psychosis (GROUP) Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379 (2013).
Berrettini, W.H. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol. Psychiatry 48, 531–538 (2000).
Lee, S.H. et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984–994 (2013).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn. (APA, Washington, DC, USA, 2013).
World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders (WHO, Geneva, 1992).
Hyman, S.E. Can neuroscience be integrated into the DSM-V? Nat. Rev. Neurosci. 8, 725–732 (2007).
The International HapMap Consortium. A haplotype map of the human genome. Nature 437, 1299–1320 (2005).
Altshuler, D.M. et al. Integrating common and rare genetic variation in diverse human populations. Nature 467, 52–58 (2010).
The 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 467, 1061–1073 (2010).
Handsaker, R.E., Korn, J.M., Nemesh, J. & McCarroll, S.A. Discovery and genotyping of genome structural polymorphism by sequencing on a population scale. Nat. Genet. 43, 269–276 (2011).
Li, Y., Willer, C., Sanna, S. & Abecasis, G. Genotype imputation. Annu. Rev. Genomics Hum. Genet. 10, 387–406 (2009).
Purcell, S.M. et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature 506, 185–190 (2014).
Fromer, M. et al. De novo mutations in schizophrenia implicate synaptic networks. Nature 506, 179–184 (2014).
Sanders, S.J. et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485, 237–241 (2012).
Iossifov, I. et al. De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285–299 (2012).
Neale, B.M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485, 242–245 (2012).
O'Roak, B.J. et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246–250 (2012).
Lambert, J.C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet. 45, 1452–1458 (2013).
Psychiatric G.C.B.D.W.G. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat. Genet. 43, 977–983 (2011).
Ripke, S. et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat. Genet. 45, 1150–1159 (2013).
Splawski, I. et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 119, 19–31 (2004).
Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).
Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
Musunuru, K. et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 466, 714–719 (2010).
McCarroll, S.A. et al. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. Nat. Genet. 40, 1107–1112 (2008).
Bauer, D.E. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342, 253–257 (2013).
The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
MacArthur, D.G. et al. A systematic survey of loss-of-function variants in human protein-coding genes. Science 335, 823–828 (2012).
Gulsuner, S. et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell 154, 518–529 (2013).
Karayiorgou, M., Flint, J., Gogos, J.A. & Malenka, R.C. The best of times, the worst of times for psychiatric disease. Nat. Neurosci. 15, 811–812 (2012).
Welch, J.M. et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 448, 894–900 (2007).
Volk, D.W. & Lewis, D.A. Prefrontal cortical circuits in schizophrenia. Curr. Top. Behav. Neurosci. 4, 485–508 (2010).
Preuss, T.M. Do rats have prefrontal cortex? The rose-woolsey-akert program reconsidered. J. Cogn. Neurosci. 7, 1–24 (1995).
Okano, H., Hikishima, K., Iriki, A. & Sasaki, E. The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin. Fetal Neonatal Med. 17, 336–340 (2012).
Nestler, E.J. & Hyman, S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 13, 1161–1169 (2010).
Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161–165 (2005).
Zuk, O. et al. Searching for missing heritability: designing rare variant association studies. Proc. Natl. Acad. Sci. USA 111, E455–E464 (2014).
Weiss, L.A. et al. A genome-wide linkage and association scan reveals novel loci for autism. Nature 461, 802–808 (2009).
The International Schizophrenia Consortium et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748–752 (2009).
Rees, E. et al. Analysis of copy number variations at 15 schizophrenia-associated loci. Br. J. Psychiatry 204, 108–114 (2014).
Sanders, S.J. et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 70, 863–885 (2011).
Abecasis, G.R. et al. An integrated map of genetic variation from 1,092 human genomes. Nature 491, 56–65 (2012).
Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96–99 (2012).
The authors are supported by the Stanley Medical Research Institute.
S.E.H. is a consultant for AstraZeneca on early-stage drug discovery and is principal investigator of a collaboration with Novartis.
- Mendelian disease
A Mendelian disease describes a single gene disorder that is caused by the presence of one (dominant) or two (recessive) alleles.
Heritability refers to the proportion of phenotypic variance of a trait, such as disease liability, that can be attributed to genetic factors.
Polygenic is a term meaning "many genes". A polygenic phenotype is influenced by more than one gene and can refer to common variants with small effects or rare variants with larger effects.
Pleiotropy is the phenomenon whereby a genetic variant influences variation in more than one trait or disease.
An allele is one of a number of alternative forms of a gene or locus. The minor allele is the less frequent allele at a locus and the major allele is the more frequent allele.
- Rare variant
Rare variant describes variants that are private to individuals and families. In some usage, the term rare variant is used more expansively to include all variants that are not common.
A locus is a place on a chromosome. A locus may contain one gene, multiple genes or no genes at all.
- Common variant
Common variant generally refers to an allele that segregates in a population at an allele frequency of at least 5%.
- Candidate gene
A candidate gene is a pre-specified gene of potential interest. Candidate gene studies are often distinguished from unbiased genome-wide studies that analyze variation in all or most genes simultaneously.
- Single-nucleotide polymorphism (SNP)
A single-nucleotide polymorphism (SNP) is a single base-pair position in the genome that varies between members of a species. The terms polymorphism and SNP generally refer to sequence variations that segregate in a population at an allele frequency of at least 1%.
The exome is the part of a genome that encodes proteins, approximately 1% of the human genome.
- Common-variant association study (CVAS)
A common-variant association study (CVAS) is a genome-wide association study to find common variants that present at different allele frequencies in affected and unaffected individuals. The term CVAS has recently been proposed as a replacement for the term GWAS, as rare-variant association studies are also association studies and are also genome wide.
- Rare-variant association study (RVAS)
A rare-variant association study (RVAS) is a genome-wide association study to discover rare variants that, as a group, present at different frequencies in affected and unaffected individuals. RVAS can be performed by whole-genome or whole-exome sequencing.
- Whole-genome sequencing (WGS)
Whole-genome sequencing (WGS) is the sequencing of all of the DNA in an individual's genome.
- Whole-exome sequencing (WES)
Whole-exome sequencing (WES) is the targeted enrichment and sequencing of the set of all protein-coding exons and non-coding RNAs in the genome (the exome). WES is performed by selectively capturing the protein-coding part of the genome by hybridization to pre-designed oligonucleotide 'baits'. The captured DNA is then sequenced. Although WES offers a less-complete view of an individual's genome sequence than whole-genome sequencing, WES has been more frequently used because of its substantially lower cost. As the price of sequencing continues to fall, WES may be gradually replaced by whole-genome sequencing.
- Case-control study
A case-control study is a study design that compares the distribution of a genetic or other variable between individuals affected with a disease (cases) and unaffected individuals (controls).
A proband is an individual being studied or reported on. The term is often used to refer to an individual affected with a disease or disorder, as distinct from their unaffected relatives.
- Trio family study
A trio family study is an analysis of probands and both of their parents. Sequencing-based trio studies often focus on de novo mutations that are present in the proband's genome, but are not detected in the genomes of his or her parents.
- Genome-wide association study (GWAS)
A genome-wide association study (GWAS) is an unbiased screen of the genome for genetic variants that present at different frequencies in affected and unaffected individuals, that is, that associate with a phenotype. Although either rare or common variants can now be studied and analyzed for association in a genome-wide way, GWAS has historically referred to a specific, early type of genome-wide study in which a genome-wide set of common polymorphisms (single nucleotide polymorphisms) is analyzed using microarray-based technologies to find disease-associated common alleles.
- Genetic background
Genetic background refers to the genotype of all genes that may modify the expression or presentation of a phenotype related to a gene of interest.
A haplotype is an arrangement of alleles along a chromosome. In population-based studies, a haplotype refers more specifically to a set of genomically nearby alleles that segregate in populations as a block or unit, as their physical linkage is seldom, if ever, disrupted by recombination.
- de novo mutation (DNM)
A de novo mutation (DNM) is a mutation that is part of an individual's genome that is not detected in the genome of either parent (although it may have arisen from a mutation in the parental germline). With the exception of de novo mutations in monozygotic twins, or those shared by siblings as a result of germline mosaicism, most new mutations are not shared by relatives and do not contribute to heritability estimates.
- Linkage disequilibrium (LD)
Linkage disequilibrium (LD) refers to the tendency of genomically nearby alleles to segregate as haplotypes or in other non-random patterns, as a result of their inheritance from shared, common ancestors, and the sparse and hotspot-concentrated distribution of recombination events in human ancestors, which allows LD relationships to persist across thousands of generations, usually at spatial scales in the tens of kilobases.
- Complex disease
A complex disease describes a disorder caused by many contributing factors, both genetic and non-genetic, and does not display a simple pattern of inheritance.
About this article
Cite this article
McCarroll, S., Feng, G. & Hyman, S. Genome-scale neurogenetics: methodology and meaning. Nat Neurosci 17, 756–763 (2014). https://doi.org/10.1038/nn.3716
This article is cited by
Future Journal of Pharmaceutical Sciences (2021)
Scientific Reports (2021)
Scientific Reports (2019)
Molecular Psychiatry (2018)
Nature Biomedical Engineering (2018)